A virulent nonencapsulated Haemophilus influenzae

Journal of Infectious Diseases

Volumn 173, Issue 1, 1996, Pages 180-186

  Nizet, Victor ^a   Colina, Kenneth F ^b   Almquist, Jon R ^b   Rubens, Craig E ^b   Smith, Arnold L ^b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFTRIAXONE; CHLORAMPHENICOL; DEXAMETHASONE; DNA; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CASE REPORT; CHILD; CLINICAL FEATURE; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LOCUS; HAEMOPHILUS INFLUENZAE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENINGITIS; NONHUMAN; OTITIS MEDIA; PHENOTYPE; PRIORITY JOURNAL; RAT; SOUTHERN BLOTTING;

EID: 0030067261     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.1.180     Document Type: Article

References (14)

1. Moxon ER, Vaughn KA. The type b capsular polysaccharide as a virulence determinant of Haemophilus influenzae: studies using clinical isolates and laboratory transformants. J Infect Dis 1981;143:517-24.
2. Turk DC. The pathogenicity of Haemophilus influenzae. J Med Microbiol 1984;18:1-16.
3. Zwahlen A, Kroll JS, Rubin LG, Moxon ER. The molecular basis of pathogenicity in Haemophilus influenzae: comparative virulence of genetically related capsular transformants and correlation with changes at the capsulation locus cap. Microb Pathog 1989;7:225-35.
4. Moxon ER, Kroll JS. The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol 1990;150:65-85.
5. Santosham M, Rivin B, Wolff M, et al. Prevention of Haemophilus type b infections in Apache and Navajo children. J Infect Dis 1992;165(suppl 1):S144-51.
6. Eskola J, Peltola H, Käyhty H, Takala AK, Mäkelä PH. Finnish efficacy trials with Haemophilus influenzae type b vaccines. J Infect Dis 1992;165(suppl 1):S137-8.
7. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
8. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1987-1993. MMWR Morb Mortal Wkly Rep 1994;43:145-7.
9. Turk DC. Clinical importance of Haemophilus influenzae. In: Sell SH, Wright PF, eds. Haemophilus influenzae epidemiology, immunology, and prevention of disease. New York: EIsevier/North Holland, 1982: 3-9.
10. Farley MM, Stephens DS, Harvey RC, Sikes RK, Wenger JD. Incidence and clinical characteristics of invasive Haemophilia influenzae disease in adults. J Infect Dis 1992;165(suppl 1):S42-3.
11. Berk SL, Holtsclaw SA, Wiener SL, Smith JK. Nontypeable Haemophilus influenzae in the elderly. Arch Intern Med 1982;142:537-9.
12. Trollfors B, Claesson B, Lagergard T, Sandberg T, Incidence, predisposing factors, and manifestations of invasive Haemophilus influenzae infection in adults. Eur J Clin Microbiol 1984;3:180-4.
13. Peltola H, Rod TO, Jonsdottir K, Bottiger M, Coolidge JAS. Life-threatening Haemophilus influenzae infections in Scandinavia: a five-country analysis of the incidence and the main clinical and bacteriologic characteristics. Rev Infect Dis 1990;12:708-15.
14. Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 1992;268:3350-2.